Friday, August 31, 2007
Patents as catalyst for new business
By Clint Fabiosa & Andrew Ong
I protect
THE global nature of pharmaceutical and biotechnological research resulted in the formation of partnerships between companies from all over the world, including the new economic powerhouses of Brazil, India, China, Cuba, the Republic of Korea and Singapore.
Biobras, for example, was a small independent laboratory in a local university in Brazil when it began its activities producing enzymes.
In 1977, it negotiated a joint-venture agreement with patent holders and pharmaceutical multinational Eli Lilly for the production of animal insulin and its commercialization in Brazil. Six years later, Biobras became an important insulin manufacturer utilizing state-of-the-art technology.
Today, Biobras is one of the only four pharmaceutical companies, and the only non-multinational company, to have the capacity and technology to produce human recombinant insulin.
The technology was developed by Biobras and was subsequently patented in Brazil, Canada, Europe, and the United States of America.
(clint.fabiosa@ovff-asiapacific.com)
For Bisaya stories from Cebu. Click here. (August 31, 2007 issue)
Write letter to the editor.Click here.
Join the Sun.Star message board.Click here. |
